Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Other Non Operating Income (2016 - 2022)

Neurocrine Biosciences' Other Non Operating Income history spans 11 years, with the latest figure at -$70.0 million for Q2 2022.

  • For Q2 2022, Other Non Operating Income changed N/A year-over-year to -$70.0 million; the TTM value through Jun 2023 reached -$70.0 million, changed 0.0%, while the annual FY2022 figure was -$70.0 million, N/A changed from the prior year.
  • Other Non Operating Income reached -$70.0 million in Q2 2022 per NBIX's latest filing, down from -$18.4 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $201000.0 in Q1 2018 to a low of -$70.0 million in Q2 2022.
  • Average Other Non Operating Income over 3 years is -$22.0 million, with a median of -$9.1 million recorded in 2018.
  • The largest YoY upside for Other Non Operating Income was 77.13% in 2018 against a maximum downside of 79.18% in 2018.
  • A 3-year view of Other Non Operating Income shows it stood at $183000.0 in 2018, then crashed by 10154.64% to -$18.4 million in 2020, then crashed by 280.43% to -$70.0 million in 2022.
  • Per Business Quant, the three most recent readings for NBIX's Other Non Operating Income are -$70.0 million (Q2 2022), -$18.4 million (Q4 2020), and $183000.0 (Q2 2018).